Catalent will continue to offer DPI development and manufacturing services at the Nottingham, UK Juniper Pharma Services facility that was part of its recently completed acquisition of Juniper Pharmaceuticals, the company says. Catalent announced its intent to acquire Juniper in July 2018.
While Catalent’s press release specified the benefits of the acquisition for its oral dose manufacturing capabilities, Juniper Pharma Services President Nikin Patel confirmed that DPI services would continue: “Combined, Juniper and Catalent have the capabilities, experience, and expertise to assist developers of inhaled dose forms, offering a range of development and manufacturing services including particle engineering and characterization for dry powder inhalers from their facility in Nottingham, UK, and across a full range of inhaled dose forms including pMDIs, DPIs, nasal sprays, nebulizers and liquid inhalers from Catalent’s facilities in Research Triangle Park, North Carolina and Woodstock, Illinois.”
Read the Catalent press release on completion of the acquisition.
